Abstract
Background: Patients with chronic kidney disease (CKD) are at increased risk of tuberculosis (TB) due to impaired cellular immunity, repeated healthcare exposure and the immunosuppressive effects of advanced kidney disease and renal replacement therapies. Accurate detection of latent tuberculosis infection (LTBI) is therefore important particularly among patients awaiting or undergoing kidney transplantation. This study evaluated the diagnostic utility of the QuantiFERON-TB Gold Plus (QFT-Plus) assay compared with the Mantoux tuberculin skin test and assessed the prevalence of TB infection across different CKD management modalities. Methods & Materials: A cross-sectional study was conducted among 94 patients with CKD at a tertiary care hospital in Bangladesh. Participants were evaluated using both the QFT-Plus interferon-gamma release assay and the Mantoux test. Demographic and clinical characteristics, CKD management modality, and TB-related findings were recorded. The prevalence of QFT-Plus positivity was compared with Mantoux positivity, and the distribution of latent TB infection was assessed across different treatment groups. Results: QFT-Plus demonstrated a substantially higher positivity rate than the Mantoux test with positivity rates of 42.6% and 14.9%, respectively. Marked discordance was observed between the two diagnostic approaches including 26 patients who were QFT-Plus positive but Mantoux negative indicating that reliance on the Mantoux test alone may miss a considerable proportion of patients with evidence of TB infection. QFT-Plus positivity was highest among kidney transplant recipients followed by patients receiving hemodialysis demonstrating a substantial burden of TB infection across advanced CKD management groups. Conclusion: QFT-Plus identified considerably more patients with evidence of TB infection than the Mantoux test in this CKD cohort. The findings support consideration of IGRA-based screening particularly among kidney transplant candidates and patients receiving hemodialysis in TB-endemic settings. Prospective multicenter studies with larger cohorts and longitudinal follow-up are warranted to establish the predictive value of QFT-Plus for subsequent active TB and to determine the clinical effectiveness of IGRA-guided preventive therapy.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2026 The Insight




PDF